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WOMAN WITH FACIAL AND NECK SWELLING
Meredith Chiaccio, MSIII and Donna Mscisz Williams, MD
Case Presentation
A 28 year-old Caucasian female, 3.5 months postpartum,
presented to the TJUH ED with facial and neck swelling. She was
in her usual state of health until approximately 1 month prior to
admission when she noted the gradual onset of neck swelling. The
neck swelling progressed to her face 4 days prior to admission;
swelling in both areas was progressive and increasingly
uncomfortable. Two months prior, the patient was treated for
sinusitis with a course of antibiotics by an allergist; this treatment
was unsuccessful, and she was referred her to an otolaryngologist,
who performed a neck ultrasound and lab work. The patient
reported that several enlarged lymph nodes were found in her
neck. The patient was then sent for a CT of the neck and chest,
which showed a mass in her mediastinum. She was planning to
follow up with a cardiothoracic surgeon, however she developed
symptomatic swelling and intermittent dysphagia. The patient
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described a sensation of choking and strangulation; these
sensations came and went at random times. She also reported
tolerating only small amounts of soft foods, such as apple sauce,
Jell-O, and yogurt. The dysphagia was present only with solid
foods, not with liquids.
The patient also complained of dull upper back pain located in
her upper right trapezius area for the past month which was
exacerbated by holding her child and other physical activities and
was alleviated somewhat by ibuprofen; this pain felt like a pulled
muscle and she rated it 4/10. She stated that chest pain, located
at her right anterior chest, had bothered her for the last 4 days;
she described this pain as piercing, sharp, 9/10 in severity, and
intermittent, with no exacerbating or ameliorating factors.
The patient’s past medical history included intermittent migraines
for several years which were well-controlled and a full term

Figure 1. Low power image of mediastinal mass shows nodular
demarcation of cells by fibrous bands.

Figure 3. High power image of Reed-Sternberg cells in a mixed
inflammatory background.

Figure 2. Higher power image showing large multi-nucleated
cells with clear cytoplasm

Figure 4. Immunostain showing CD15+ staining of binucleated
Reed Sternberg cells.
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uncomplicated vaginal delivery four months prior after which she
breast fed for 6.5 weeks. Her surgical history was significant only
for appendectomy and breast augmentation. She was taking no
medications and reported allergies to penicillin, latex, iodine, and
shellfish, which all cause pruritic rash. She denied alcohol, tobacco,
or substance abuse. Her family history was noncontributory.
Her review of systems was significant for 7 lb weight gain in the
last week, congested and swollen right ear, bilateral sinus pressure,
hoarseness, bulging veins which appeared in left neck 1 week ago,
and occasional pulsations in her neck bilaterally. She reported
edema in the right hand, bilateral swelling of hands and fingers
(right greater than left, worsening recently), as well as tingling and
numbness in the right fingertips. The patient reported feeling lightheaded when sitting up from supine or when bending over to pick
something up off floor, and she felt that her neck swelling worsened
when leaning forward. The patient also reported intermittent
throbbing headaches, minimally relieved by ibuprofen.
On physical exam, the patient was in no acute distress with stable
vital signs. The head and neck exam was significant for an
enlarged, well-developed neck with visible tortuous collateral
vessels bulging on the left side. Neck circumference was 31.5 cm.
Sternocleidomastoids were prominent bilaterally. There was no
cervical or supraclavicular lymphadenopathy, nodules, or enlarged
thyroid. The patient had maxillary and frontal sinus tenderness to
palpation bilaterally, right greater than left. No stridor was
appreciated. Generalized distension in neck prevented clear
assessment of jugular venous pressure. Pemberton sign was
negative. Examination of the lungs revealed decreased breath
sounds on right side. Extremity exam revealed dusky/dark
appearance of the skin of right extremities and edema of right
hand. No axillary or inguinal lymphadenopathy present.

Assessment
The constellation of this patient’s history, signs and symptoms,
labs, imaging studies, and knowledge of presence of mediastinal
mass were consistent with Superior Vena Cava (SVC) Syndrome.
This diagnosis was supported by known presence of anterior
superior mediastinal mass with SVC displacement, swelling of the
neck and face, development of collateral neck vessels, unilateral
cyanosis, swelling and tingling and numbness of the upper
extremity, and positional lightheadedness.

Hospital course
Initial serologic studies were unrevealing. Chest x-ray in the ED
revealed a widened superior mediasinum. CT of the chest
performed shortly prior to presentation forwarded from an
outside institution showed a large homogeneously enhancing
anterior mediastinal soft tissue mass insinuating between aortic
branch vessels, displacing the SVC laterally with compression.
The mass was measured at 9.4cm x 4.9cm x 13.8cm. The patient
underwent bronchosopy and transbronchial biopsy of the
mediastinal mass, but pathology was indeterminate.

Cardiothoracic surgery was consulted for mediastinoscopy, and
biopsies revealed Hodgkin’s lymphoma, nodular sclerosing
subtype (see Figures 1-4). Both Medical Oncology and Radiation
Oncology were consulted, and treatment plan was made. The
patient underwent bilateral bone marrow biopsies which were
negative. Remainder of the staging work-up was significant only
for enlarged lymph nodes in the prevascular and pretracheal
spaces. The patient’s disease was staged at IIA.

Discussion
Superior Vena Cava syndrome (SVCS) occurs when the SVC is
invaded or externally compressed by a mass or thrombosed. SVCS
encompasses a classic constellation of signs and symptoms including
facial edema, dyspnea, tachypnea, cyanosis, venous distension,
headache, and plethora. Other signs include cough, arm edema, a
feeling of head fullness often exacerbated by lying down or bending
forward; more seriously, it could present as respiratory distress from
tracheal involvement. Pemberton’s sign is the development of facial
plethora, inspiratory stridor, and non-pulsatile JVP elevation when
a patient with SVC syndrome lifts the arms over the head. While
dysphagia, hoarseness, and stridor are not included in the definition
of SVCS because they result from compression of mediastinal
structures other than the SVC (esophagus, laryngeal nerve, and
trachea respectively), their presence is negatively correlated with
prognosis. Presentation depends on both the location and rate of
growth of the mass; growth rate also determines how well the
syndrome can be compensated by new collateral circulation.
Important collateral veins arise from the azygos, lateral thoracic,
paraspinous, and internal mammary veins.
Approximately 85% of cases of SVCS are caused by malignant
tumors; the rest are due to infection and thrombosis. Up to 60%
of patients presenting with SVCS due to underlying malignancy
present without a known diagnosis of cancer. The most common
malignant causes of SVCS are lung cancer, lymphoma, thymoma,
mediastinal germ cell tumors, and solid organ tumors metastatic
to the mediastinum. Bronchogenic carcinoma and lymphoma
alone account for 94% of cases of SVC syndrome. Fibrosing
mediastinitis accounts for up to 50% of nonmalignant causes of
SVCS. This clinical entity is often caused by excessive host cell
response to a prior Histoplasma capsulatum infection; however,
other causative infections include aspergillosis, blastomycosis,
actinomycosis, tuberculosis, and Bancroftian filariasis. SVC
thrombosis can also occur secondary to indwelling central venous
catheters and pacemaker leads.
Lung carcinoma is the most common cause of SVCS and does so
via compression or direct SVC invasion by tumor or via
mediastinal lymphadenopathy. Two to four percent of patients
with lung carcinoma develop SVCS during the course of their
disease. Up to 20% of patients with small cell lung cancer develop
SVCS because of the central location of these tumors; peripherally
arising lung tumors, including adenocarcinoma and large cell
carcinoma, are less likely to cause SVC involvement. Small cell
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lung cancer accounts for approximately 40% of all cases of SVC
syndrome due to lung cancer, with squamous cell carcinoma
making up another 18%.
Lymphoma, almost always Non-Hodgkin’s type, is the second most
common cause of SVCS. Approximately 2-4% of patients with
lymphoma develop SVCS, via lymph node enlargement. The most
common lymphomas associated with SVCS are diffuse large B-cell
and lymphoblastic lymphomas. Hodgkin’s lymphoma, despite its
common presentation with mediastinal lymphadenopathy, rarely
causes SVCS.
In addition to lung carcinoma and lymphoma, thymoma and
germ cell tumors are also among the more common malignant
causes of SVC syndrome.

Anterior Mediastinal Masses
Approximately 2/3 of all mediastinal tumors are benign. Anterior
mediastinal masses make up 60% of all mediastinal masses. The
most common neoplasias of the anterior mediastinum include the
“4 Ts” – thymoma, thyroid tumor, germ cell tumors (teratomas),
and “terrible” lymphomas. Other anterior mediastinal neoplasms
include thymic carcinoid, thymolipoma, and parathyroid
adenomas. Thymic cyst, lymphangioma, and intrathoracic goiter
comprise the non-neoplastic causes of anterior mediastinal masses.
Lymphoma is the second most common primary anterior
mediastinal tumor, second only to thymoma, and accounts for
10-20% of primary mediastinal masses overall. While lymphoma
can affect any mediastinal compartment, most are located in the
anterosuperior mediastinum and the remainder in the middle
mediastinum. These lymphomas typically present with large,
bulky tumors, often with involvement of adjacent intrathoracic
structures. While Hodgkin’s lymphoma represents only 25-30%
of all cases of lymphomas, it is the most common mediastinal
lymphoma; the nodular sclerosing subtype is the most common,
and it has particular predilection for the anterior mediastinum.
Hodgkin’s lymphoma will be discussed below. The most common
primary mediastinal Non-Hodgkin’s lymphomas are large B-cell
lymphoma and lymphoblastic lymphoma. Patients with NHLs
are typically older than age 55; 85% present with advanced disease
and typically have constitutional (“B”) symptoms, generalized
lymphadenopathy, and extensive extranodal disease at time of
diagnosis. Indolent NHLs, as compared to aggressive NHLs,
generally have a more favorable histologic condition, occur
nodally, and are more clinically advanced at presentation.
Treatment of NHL depends on histologic classification, site of
presentation, and disease extent. Patients with indolent NHLs are
treated palliatively with radiation and chemotherapy if necessary,
as they typically have a more prolonged disease course, are rarely
cured, and almost always have recurrence. Patients with aggressive
NHLs are treated with combination chemotherapy and radiation,
with possible bone marrow transplantation. Negative prognostic
factors for NHLs include extensive extranodal disease and large
tumor size at presentation, and slow response to treatment.
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Hodgkin’s Lymphoma: Diagnosis, Staging, and Treatment
Hodgkin’s lymphoma, first described by Sir Thomas Hodgkin in
1832, is a malignant lymphoma with a bimodal peak incidence in
the second and fifth decades, more commonly found in males.
Diagnosis of Hodgkin’s lymphoma requires presence of the classic
Reed-Sternberg cell – with its abundant basophilic cytoplasm and
two large nuclei with pale chromatin and distinct eosinophilic
nucleoli – in a mixed inflammatory background of reactive
lymphocytes, macrophages, plasma cells, eosinophils, and a
disrupted nodal architecture with fibrotic stroma. Only recently
were Reed-Sternberg cells discovered to be of B-cell origin; though
these cells lack B-cell markers such as CD20 and the B-cell receptor,
their precursors are definitively germinal center B-cells that escape
negative selection and apoptosis by acquisition of a survival
advantage through an as yet unknown mechanism. Epstein-Barr
Virus is thought to play a role in the malignant transformation of
Reed-Sternberg precursor cells by upregulation of antiapoptotic
genes and inhibition of the FAS-signalling pathway.
The two main types of HL are classic HL and lymphocytepredominant HL; classic HL is further classified into 4 subtypes,
including nodular sclerosing, lymphocyte rich, lymphocyte
depleted, and mixed cellularity. Classic HL accounts for 95% of
all cases of HL. This discussion will center around the nodular
sclerosing subtype as it is the most common, accounting for nearly
80% of cases of HL. With a predominance in young, female
patients, the nodular sclerosing subtype is characterized by a
nodular growth pattern with sclerosing/fibrotic collagenous
banding. The pathology report for the patient in the above case
stated that “the lymph node architecture appeared effaced by
bands of collagen fibrosis, which subdivide the lymph node into
smaller nodules.” Nodular sclerosing Hodgkin’s lymphoma has a
unique predilection for the anterior mediastinum, especially the
thymus, and may manifest itself as a discrete, lobulated anterior
superior mediastinal mass.
The most common clinical presentation of HL is enlarged
nontender cervical and/or supraclavicular lymphadenopathy, and
bulky mediastinal lymphadenopathy is additionally characteristic
of nodular sclerosing HL. Patients with mediastinal involvement
tend to be younger than those without mediastinal disease;
mediastinal involvement can manifest as chest pain, cough,
wheezing, dysphagia, or SVC syndrome, discussed above. At
presentation, 25% of patients with HL have constitutional “B”
symptoms of fever (including cyclic Pel-Ebstein curves), weight
loss and night sweats. There is also an unusual association between
alcohol consumption and lymph node pain or generalized pruritis
in patients with Hodgkin’s lymphoma.
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The Modified (Cotswold) Ann Arbor Staging Classification is typically used to stage HL
I

II

III

III1

III2

IV

Single node region
or a lymphoid structure
(spleen, thymus,
Waldeyer’s ring) or
involvement of a single
extralymphatic site)

Two or more node
regions on the same
side of the diaphragm,
localized contiguous
involvement of only one
extranodal organ or side
and node region on the
same side of the diaphragm

Node regions involved
on both sides of
diaphragm, and/or
involvement of spleen,
or localized contiguous
involvement of only
one extranodal organ
site or both.

With or without
involvement of
splenic, hilar, celiac,
or portal nodes.

With involvement
of para-aortic, iliac,
and mesenteric nodes.

Diffuse or disseminated
involvement of one
or more extranodal
organs or tissues,
with our without
associated node
involvement.

Modifiers
A

B

X

E

constitutional “B” symptoms absent

fever > 38°C, weight loss > 10%
in 6 months, night sweats

bulky disease (widened mediastinum
by >1/3 or presence of nodal mass
w/ max dimension >10cm)

involvement of a single extranodal
site that is contiguous or proximal
to the known nodal site

Anatomic staging helps distinguish patients that would likely
benefit from radiation therapy alone from those requiring
systemic treatment. Most patients with HL present with disease
localized above the diaphragm; approximately 50% of patients
present in stage I or II, and less than 5-10% have extranodal
disease at time of diagnosis. Subtype and stage are the two most
important prognostic factors in HL: the nodular sclerosis subtype
carries a very good prognosis, while lymphocyte-depleted HL
carries the worst prognosis of the HL subtypes. Constitutional
symptoms, age greater than 45, extranodal or bulky mediastinal
disease, high ESR or LDH, and greater than five splenic disease
foci are adverse prognostic factors.

effects during the initial treatment phase and had increased
incidence of late complications of sterility and secondary
malignancies, especially myelodysplastic syndrome and secondary
acute leukemia, without any gain of efficacy. Four cycles of ABVD
are used in early-stage disease and six to eight are used in advancedstage disease. Relapsed disseminated disease is treated with highdose chemotherapy and autologous bone marrow transplantation.

Follow-up
The patient described in the above case can expect a 12-year
freedom from progression of approximately 94% and an overall
survival rate of 94%.
■

Patients with stage IA, IB, IIA, and IIB disease are treated with
combined-modality therapy of combination chemotherapy plus
involved-field irradiation. This concept has replaced prior
treatment plans of radiation therapy alone, which was associated
with a high incidence of complications including gonadal toxicity
and secondary malignancies. Combined-modality therapy also
provides improved disease control and lower morbidity. Patients
with stage III or IV disease receive combination chemotherapy in
occasional combination with radiation.
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